Kenvue presents new skin research: Kenvue stock sits 13.61 percent below its high

Published on 10/06/2026 at 12:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 3.00 percent to USD 3.96 billion. Kenvue stock costs EUR 15.50 on October 6, 2026 after EUR 15.43.

Photorealistisches Architektur-Render eines gläsernen Bürogebäudes bei Sonnenuntergang — Architektur-Rendering eines modernen gläsernen Bürogebäudes steht symbolisch für den Unternehmenssitz von Kenvue mit ISIN US49177J1025, Illustration mit AI erstellt.

Kenvue (ISIN US49177J1025) presented new scientific evidence for its Neutrogena, Aveeno and Regaine brands on September 30, 2026, according to Kenvue. On the NYSE, the stock was last at USD 17.39 on October 5, 2026 at 4:00 p.m. ET, placing it 13.61 percent below its USD 20.13 52-week high.

Skin research meets steady sales

Kenvue's update highlighted new evidence supporting skin and hair health products across three major brands. The research adds a product-development angle to a consumer-health portfolio that also includes Tylenol, Zyrtec and Listerine.

For the second quarter of 2026, Kenvue reported net sales of USD 3.96 billion, up 3.00 percent from the second quarter of 2025. Diluted earnings per share increased 9.00 percent to USD 0.24, while adjusted diluted earnings per share rose 7.00 percent to USD 0.31, according to Kenvue on August 6, 2026.

Analysts keep a Hold consensus

MarketBeat reported on October 6, 2026 that 10 of 12 research firms rated Kenvue Hold and two rated it Buy. The average one-year price objective was USD 19.00, which is 9.26 percent above the October 5 NYSE price of USD 17.39.

The recent earnings comparison was less decisive: second-quarter adjusted diluted earnings per share reached USD 0.31 against a USD 0.32 consensus estimate, while revenue of USD 3.96 billion came in against expectations of USD 3.97 billion. That combination places the emphasis on sales execution and brand innovation rather than on a broad earnings surprise.

Dividend supports the valuation case

Kenvue's board declared a quarterly dividend of USD 0.21 per share, payable October 2, 2026 to shareholders of record on September 21, 2026, according to MarketScreener. MarketBeat reported an annualized dividend of USD 0.84 and a 4.80 percent yield on October 6, 2026, alongside a 96.55 percent payout ratio.

Euro quote edges higher

Kenvue was trading at EUR 15.50 at Lang & Schwarz on October 6, 2026 at 12:33 p.m. CEST, up 0.45 percent versus the prior close of EUR 15.43 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Kenvue stock.